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Postoperative duplex scan surveillance of
axillofemoral bypass grafts
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Lloyd M. Taylor, Jr, MD, Richard A. Yeager, MD, James M. Edwards, MD, and Gregory L. Moneta,
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Objective: Duplex scan surveillance (DS) for axillofemoral bypass grafts (AxFBGs) has not been extensively studied. The
intent of this study was twofold: 1, to characterize the flow velocities within AxFBGs; and 2, to determine whether
postoperative DS is useful in assessment of future patency of AxFBGs.
Methods: We identified all patients who underwent AxFBG procedures between January 1996 and January 2001 at our
combined university and Veterans Affairs hospital vascular surgical service. All grafts were performed with ringed 8-mm
polytetrafluoroethylene with the distal limb of the axillofemoral component anastomosed to the hood of the femoral-
femoral graft. DS was every 3 months for 1 year and every 6 months thereafter. Duplex scan results were compared in
primarily patent grafts with grafts that thrombosed. Graft failures from infection were excluded. Influences of
ankle-brachial index, blood pressure, outflow patency, operative indication, and comorbidities on graft patency were
analyzed.
Results: One hundred twenty patients underwent AxFBG procedures. Twenty-eight were excluded because of infection or
death before surveillance examination. Fourteen were lost to follow-up, 23 had failed grafts from occlusion, and 55 had
grafts that remained patent. In the 78 patients evaluated during long-term follow-up period, the mean peak systolic
velocities (PSVs) at the proximal (axillary) anastomosis during the first postoperative year ranged from 153 to 194 cm/s.
Mean PSVs at the mid portion of the axillofemoral graft during the first postoperative year ranged from 100 to 125 cm/s,
whereas those for the distal axillofemoral anastomosis ranged from 93 to 129 cm/s. Mean midgraft and distal
anastomotic velocities obtained before thrombosis were significantly lower in the thrombosed grafts compared with the
last recorded velocities at the same sites in the patent grafts (mean PSV, 84 versus 112 cm/s; P  .015; mean PSV, 89
versus 127 cm/s; P  .024, respectively). Forty-eight percent of occluded grafts had a mean midgraft PSV at last
observation of less than 80 cm/s. Blood pressure correlated with midgraft velocity (r  0.415; P < .05). With
multivariate logistic regression analysis, a mean midgraft velocity less than 80 cm/s was the sole independent factor
associated with graft failure (P < .01). No patients with midgraft velocities greater than 155 cm/s had occlusion.
Conclusion: Flow velocity varies widely within and among AxFBGs. Patency of AxFBGs is associated with higher midgraft
PSV, and thrombosis with midgraft velocities less than 80 cm/s. (J Vasc Surg 2003;37:54-61.)
Axillofemoral bypass grafts (AxFBGs) with polytetra-
fluoroethylene have been used extensively for the treatment
of critical limb ischemia in patients with unsuitable condi-
tions for abdominal aortic surgery and in patients with
primary aortic or aortic graft infections.1,2 Studies have
shown midterm patency rates approaching those achieved
with aortofemoral bypass.3,4
Duplex ultrasound scan has been shown to be effective
in detection of failing lower extremity autologous vein
grafts.5-7 Studies evaluating duplex scan surveillance (DS)
of lower extremity prosthetic bypass grafts, however, have
yielded conflicting results. Some reports suggest improved
patency and limb salvage rates with routine DS of pros-
thetic grafts.8-10 Flow characteristics through prosthetic
grafts can be important in determination of patency, per-
haps justifying surveillance.11 Prosthetic grafts can, how-
ever, also occlude without identifiable stenotic lesions,
raising the question of the utility of ultrasound scan surveil-
lance.12,13 Some authors have therefore concluded that a
surveillance program does not influence the patency of
prosthetic grafts and that routine surveillance is not justi-
fied.7,14,15
Duplex scan–derived flow characteristics of AxFBGs
have not been well characterized. In this study, we exam-
ined axillofemoral graft flow velocities detected with duplex
scanning and characterized flow parameters and patient
characteristics of AxFBGs associated with subsequent graft
patency or thrombosis.
PATIENTS AND METHODS
Between January 1, 1996, and January 1, 2001, 120
patients underwent AxFBG procedures with externally sup-
ported 8-mm polytetrafluoroethylene at Oregon Health &
Science University and the Portland Veteran’s Affairs Med-
ical Center. Patients were included in the analysis if they
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had undergone at least one postoperative duplex scan graft
flow study. Patients with grafts that failed from infection
were excluded.
All operations were performed in a standardized fash-
ion, with the proximal graft anastomosed to the axillary
artery and tunneled deep and lateral to the pectoralis minor
muscle. A small amount of redundancy was left in the
proximal graft to decrease the risk of proximal graft disrup-
tion.4,16 If an axillobifemoral bypass was performed, the
distal limb of the axillofemoral graft was anastomosed to
the anastomotic hood of one side of the femoral-femoral
graft. Preoperative arteriograms were reviewed to deter-
mine outflow patency. Outflow patency was defined as
either a patent superficial femoral artery or a patent infrain-
guinal bypass graft.
DS was carried out every 3 months for the first postop-
erative year and every 6 months thereafter. The DS proto-
col consisted of measurement of peak systolic flow veloci-
ties (PSV) at the native inflow and outflow arteries, at all
proximal and distal anastomoses, and at the midportion of
both the axillofemoral and femoral-femoral components.
Bilateral arm blood pressures and ankle-brachial indices
(ABI) were also recorded at each follow-up visit. All duplex
scan examinations were performed by registered vascular
technologists with either Hewlett-Packard (HP 4500,
5500, Hewlett-Packard Co, Palo Alto, Calif) or Acuson
(Acuson 128 XP Computed Sonography, Mountain View,
Calif) duplex scanners.
Statistical analyses were performed with comparison of
the last recorded study obtained in primarily patent grafts
(patent group) with the last recorded study obtained before
occlusion (occluded group). Data were analyzed with Stu-
dent t tests, 2 analysis, and multivariate logistic regression
analyses with SPSS (version 10.1, SPSS, Inc, Chicago, Ill).
A P value of less than .05 was considered to be significant.
RESULTS
One hundred twenty patients underwent AxFBG pro-
cedures during the study period. Thirteen patients were
excluded from analysis because of infection as the cause of
graft failure. Fifteen patients died before a DS examination
was obtained, and 14 patients were lost to follow-up.
Seventy-eight patients, therefore, qualified for inclusion in
this study. Twenty-three patients (29%) had graft occlusion
(occluded group), and 55 (71%) had patent grafts through-
out the follow-up period (patent group). The mean age was
67 years (range, 45 to 87 years). Follow-up ranged from 1
to 64 months (mean follow-up, 25 months). Patient char-
acteristics and risk factors for both groups are listed in Table
I.
Limb salvage was the indication for AxFBG in 62% of
patients (Table II). Only 16% of the operations were done
for short distance claudication. The remaining 22% were
done for either aortic graft infection or thrombosis. Forty
percent of patients had either bilaterally patent superficial
femoral arteries or bilaterally patent infrainguinal bypass
grafts or a combination before surgery, 33% had a single
limb with patent superficial femoral arteries or infrainguinal
bypasses, and 21% had only patent profunda femoral arter-
ies (Table III). Six percent of the patients (n  5) had no
preoperative data regarding outflow patency. All five pa-
tients had acute limb-threatening ischemia either secondary
to acute native aortic occlusion (n  2) or acute graft
occlusion of a previously placed aortobifemoral graft (n 
1), axillofemoral graft (n  1), or femoral-femoral graft
(n 1). These five patients were excluded from the analysis
of the effect of outflow on patency. No significant differ-
ences were seen between the continuously patent and sub-
sequently occluded grafts with respect to operative indica-
tions, outflow patency, or patient comorbidities.
The mean of the PSVs in the individual grafts at se-
quential locations along the axillofemoral grafts are listed in
Table IV for the first 12 postoperative months. Figs 1
through 3 show the differences between the patent and
occluded groups at three sites along the axillofemoral graft
during the first postoperative year. A significant difference
was seen between the PSV at the proximal anastomosis
between the two groups at 12 months, with the PSV of the
Table I. Patient characteristics and comorbidities among
78 patients undergoing axillofemoral bypass grafting
between January 1996 and January 2001
Patent*
(n  55)
Occluded†
(n  23) P value‡
Mean age (y; range) 68 (50-84) 65 (45-87)
Male gender 37 (67%) 14 (61%) 1.0
Female gender 18 (33%) 9 (39%)
Axillobifemoral bypass 45 (82%) 21 (91%) .30
Axillounifemoral bypass 10 (18%) 2 (9%)
Tobacco use 45 (82% 20 (87%) .58
Hypertension 43 (78%) 12 (52%) .02
Coronary artery disease 29 (53%) 13 (56%) .76
Hyperlipidemia 15 (27%) 6 (26%) .92
Warfarin sodium use 11 (20%) 7 (30%) .32
Diabetes mellitus 13 (24%) 4 (17%) .45
Hypercoagulable state 3 (6%) 2 (9%) .60
Chronic renal insufficiency 3 (6%) 3 (13%) .26
*Patent group: patients with grafts remaining patent throughout follow-up.
†Occluded group: patients with grafts occluding during follow-up.
‡Student t test.
Table II. Operative indications of all 78 patients
undergoing axillofemoral grafting during study period
Patent*
(n  55)
Occluded†
(n  23) P value‡
Rest pain 30 (55%) 11 (48%) .59
Claudication 9 (16%) 6 (26%) .33
Ulcer/gangrene 13 (24%) 3 (13%) .23
Aortic graft infection 7 (13%) 2 (9%) .62
Inflow occlusion§ 8 (14%) 3 (13%) .86
*Patent group: patients with grafts remaining patent throughout follow-up.
†Occluded group: patients with grafts occluding during follow-up.
‡Student t test.
§Native aortic occlusion (n  3), aortofemoral graft thrombosis (n  3),
axillofemoral graft thrombosis (n  2), femoral-femoral graft thrombosis
(n  3).
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occluded grafts significantly lower than that of the patent
grafts (P  .013). No apparent trends were seen toward
increasing or decreasing velocities identified at any site.
We compared the last recorded graft flow study in the
primarily patent grafts with the last study obtained before
occlusion in the occluded group. Univariate analysis results
revealed that the mean PSV at the midportion of the
axillofemoral graft was significantly lower in the occluded
group compared with the patent group (mean PSV, 84
versus 112 cm/s, respectively; P  .015; Fig 4). No pa-
tients had a midaxillofemoral PSV greater than 155 cm/s
with graft occlusion. Only one patient had a midaxil-
lofemoral PSV greater than 140 cm/s with graft occlusion.
Also, a significantly lower mean PSV was seen at the distal
anastomosis of the axillofemoral graft in the occluded
group compared with the patent group (mean PSV, 89
versus 127 cm/s; P .024; Fig 5). However, no significant
difference was seen between the occluded and patent
groups in comparison of the mean PSV at the proximal
anastomosis (mean PSV, 162 versus 209 cm/s; P  .16;
Fig 6). Blood pressure correlated with midaxillofemoral
PSV (r  0.286; P  .02).
After examination of these results, we determined the
risk of graft occlusion and patency for every 10 cm/s
difference between 60 and 150 cm/s. We found that a
midaxillofemoral PSV greater than 140 cm/s resulted in a
Table III. Percentage of patients with patent native superficial femoral artery or infrainguinal bypass as assessed with
preoperative arteriography if available
Patent*
(n  55)
Occluded†
(n  23)
Patent SFA or IIB bilaterally 20 (37%) 11 (48%)
Single limb with patent SFA or IIB 21 (38%) 5 (22%)
Patent profunda femoral artery only 11 (20%) 5 (22%)
No outflow data before surgery 3 (5%) 2 (8%)
*Patent group: patients with grafts remaining patent throughout follow-up.
†Occluded group: patients with grafts occluding during follow-up.
SFA, Superficial femoral artery; IIB, in frainguinal bypass.
Table IV. Mean PSVs (cm/s  standard error) for three sites along axillofemoral graft components during first 12
postoperative months
Site 3 mo 6 mo 9 mo 12 mo
Proximal axillary anastomosis 153.5  11 157.3  18 194.1  24 154.9  22
(n  24) (n  16) (n  16) (n  17)
Midgraft axillofemoral component 107.2  9 108.1  13 125.1  9 100.7  9
(n  26) (n  21) (n  20) (n  22)
Distal axillofemoral anastomosis 97.9  8 108.5  13 129.5  14 93.6  10
(n  26) (n  19) (n  20) (n  18)
Fig 1. Comparison of mean PSV at proximal axillary anastomosis for both grafts remaining continuously patent and
grafts with thrombosis during observation during first 12 postoperative months.
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94% patency rate. We also found that 48% of all grafts with
a midaxillofemoral PSV less than 80 cm/s occluded, and
82% of all grafts with a midaxillofemoral PSV greater than
80 cm/s remained patent (2  6.03; P  .014; Fig 7).
The results of the multivariate logistic regression anal-
ysis showed that a mean PSV less than 80 cm/s at the
midportion of the axillofemoral grafts was the only inde-
pendent factor associated with an increased risk of graft
failure (odds ratio, 7.09; 95% CI, 2.0 to 24.0; P .002; Fig
8). Neither outflow patency, operative indication, patient
comorbidities, ABI, nor blood pressure was an indepen-
dent factor associated with graft failure.
DISCUSSION
In this study, we characterized the PSV seen at specific
locations through AxFBG. We compared the mean PSVs of
patent grafts with those of occluded grafts and found no
trend toward increasing or decreasing velocities over time
in grafts that went on to occlude. Although we were unable
Fig 2. Comparison of mean PSV at midportion of axillofemoral graft for both grafts remaining continuously patent
and grafts with thrombosis during observation during first 12 postoperative months.
Fig 3. Comparison of mean PSV at distal axillofemoral anastomosis for both grafts remaining continuously patent and
grafts with thrombosis during observation during first 12 postoperative months.
Fig 4. Univariate analysis of mean PSV at midportion of axil-
lofemoral component comparing last recorded study in patent
grafts with last study obtained before occlusion in subsequently
occluded grafts.
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to show that DS of AxFBG could be used to predict graft
failure, we did find that a midaxillofemoral PSV less than 80
cm/s is an independent factor associated with an increased
risk of graft occlusion. In addition, we showed that a
midgraft PSV greater than 140 cm/s is a significant predic-
tor of graft patency, as 94% of grafts with velocities above
this level remained patent (Fig 4).
That the identification of failing infrainguinal vein by-
pass grafts with duplex ultrasound scan is effective in pro-
longing patency is well accepted.5,7,17 Before this report,
however, most studies evaluating the efficacy of DS for
improving the patency of infrainguinal prosthetic bypass
grafts have shown no potential benefit.7,14,15 Lundell and
colleagues7 performed a prospective randomized trial eval-
uating the efficacy of an intensive DS protocol for improv-
ing patency and showed that there was a significant im-
provement in assisted primary patency and secondary
patency with intensive surveillance compared with routine
surveillance for evaluating vein grafts but that there was no
significant improvement in either primary assisted or sec-
ondary patency with prosthetic or composite grafts.
In contrast, Sanchez et al8 retrospectively reviewed 85
patients with failing polytetrafluoroethylene grafts, seven
with AxFBG, and showed that the predominant lesions
responsible for graft failure were inflow and outflow lesions.
With treatment of these lesions, they were able to achieve a
5-year primary assisted patency rate of 71% and a limb
salvage rate of 73%. This led the authors to conclude that
DS for prosthetic grafts is useful in prolonging patency.
The number of AxFBGs in that study was low, and they did
not look specifically at the differences between various types
of prosthetic grafts.
Calligaro et al9 were able to show that DS was more
sensitive than clinical measures, such as ABI, pulse exami-
nation, or pulse volume recordings, for detection of failing
prosthetic grafts, including AxFBG, but they did not show
improvement in patency of these grafts. The number of
AxFBGs in their study was also small (n  13). Because of
the improved sensitivity of DS compared with clinical mea-
sures (81% versus 24%), they concluded that DS of pros-
thetic grafts is worthwhile, although this study also did not
stratify the results on the basis of location of the grafts.
Examination of the flow velocities at various sites along
the axillofemoral grafts in this study shows that the veloci-
ties vary widely within, and among, the grafts. The variabil-
ity in the flow velocities among grafts was independent of
outflow patency, which is consistent with our previous
observation that outflow patency does not influence graft
patency3 but inconsistent with other authors who have
shown that outflow does affect patency.18,19 Our data
indicate that a patent superficial femoral artery is not nec-
essary to provide the low resistance state needed to improve
patency. A patent profunda femoral artery may be a suffi-
cient outflow source, as the primary determinant of blood
flow into an artery is arteriolar resistance.20 Alternatively,
the degree of retrograde flow into the pelvis may also help
to provide decreased resistance to maintain patency.
Understandably, the number of grafts in this study
decreases over time as grafts occlude. This may affect the
Fig 6. Univariate analysis of mean PSV at proximal axillary
anastomosis comparing last recorded study in patent grafts with
last study obtained before occlusion in subsequently occluded
grafts.
Fig 5. Univariate analysis of mean PSV at distal axillofemoral
anastomosis comparing last recorded study in patent grafts with
last study obtained before occlusion in subsequently occluded
grafts.
Fig 7. Percent risk of subsequent graft occlusion with midaxil-
lofemoral PSV less than or greater than 80 cm/s.
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evaluation of velocity changes over time. The number of
grafts that had complete data at each time point was low.
However, this does not affect the evaluation of the last
recorded study obtained before occlusion or the last study
obtained in grafts that are still patent. This is the more
important evaluation to make because if a decision must be
made regarding a threatened graft, the most recent study is
the most vital.
It should be noted that the number of graft failures
observed in this study exceeds what we may have expected
on the basis of our previously published results.3 The
patients in this analysis are obviously a different and smaller
group from a different period of time. We are aggressive in
performance of AxFBG procedures and offer them to pa-
tients at high risk with advanced disease. Our data will
eventually need to be reanalyzed to determine whether this
aggressive posture is justified, perhaps with comparison of
patients from two time periods.
We expected to find less variability in the flow velocities
within grafts because all grafts have a uniform diameter and
are constructed in a uniform fashion. One plausible expla-
nation is that these grafts do not have laminar flow through
them either because of the pulsatile nature of blood pres-
sure or the viscosity of blood. This is speculative, and a close
examination of the duplex color flow characteristics might
answer this question. We did find a positive correlation
between blood pressure and midgraft flow velocity; how-
ever, blood pressure was not an independent factor influ-
encing graft failure in the multivariate analysis.
It is interesting to note that the presence of a femoral-
femoral graft was not an independent factor associated with
graft patency in the multivariate analysis. Other authors
have found similar results.18,21 This is in contradiction to
the findings of LoGerfo et al22 who showed that axillob-
ifemoral grafts had superior patency when compared with
axillounifemoral grafts. The number of axillounifemoral
grafts in our study was small (12 grafts total: 10 patent, two
occluded), and it is possible that had an equal number of
each configuration been used that a true difference might
have been observed. Whether an axillobifemoral graft por-
tends improved patency over axillounifemoral grafts re-
mains an unanswered question.
The results of this study show that AxFBGs have a
greater likelihood of remaining patent if the flow velocities
through the midportion of the graft remain above a certain
level (140 cm/s in our study). The implication is that low
flow velocities are detrimental and may lead to thrombosis.
Other studies have shown that low flow velocities through
bypass grafts predict failure.11,23 Bandyk, Cato, and
Towne11 evaluated infrainguinal in situ vein bypasses and
found that postoperative PSV less than 45 cm/s identified
grafts at risk for failure and recommended angiographic
evaluation to identify correctable lesions.
Understandably, most clinicians become concerned
about the development of high flow velocities within by-
pass grafts that may imply the presence of a stenosis. In
consideration of autologous vein bypass grafts, this fact is
true. However, in the case of prosthetic grafts, it appears a
high PSV does not necessarily identify a graft at risk for
failure. Studies evaluating flow through prosthetic grafts
have determined that many grafts will fail without an iden-
tifiable area of stenosis.12,13 This is particularly true for
smaller diameter grafts.24,25
It has been suggested that patients with low postoper-
ative PSVs and no identifiable areas of stenosis should
undergo systemic anticoagulation therapy to improve pros-
thetic graft patency.17,26 However, a recent multicenter,
prospective, randomized trial has been performed compar-
ing warfarin and aspirin, in combination, with aspirin alone
to determine whether improved patency was achieved with
systemic anticoagulation.27 The results of this study
showed that only prosthetic, above-knee bypasses, which
were constructed with 6-mm grafts, benefited from antico-
agulation therapy. No difference was found in patients with
AxFBG, although the number was small, likely because
6-mm grafts were rarely used for this operation. Patients
treated with warfarin and aspirin had significantly more
hemorrhagic events and significantly higher mortality than
patients treated with aspirin alone.27
Fig 8. Multivariate odds ratio of graft failure with midaxillofemoral PSV less than 80 cm/s, outflow patency, blood
pressure, ABI, smoking, presence of femoral-femoral bypass, and warfarin use, with 95 percent CIs.
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The results of this study show that a midaxillofemoral
peak systolic flow velocity less than 80 cm/s is associated
with an increased risk of graft occlusion and that a PVS
greater than 140 cm/s through the same area is associated
with continued graft patency. Patency of AxFBG was inde-
pendent of outflow patency, blood pressure, operative in-
dication, smoking, warfarin use, or the presence of a fem-
oral-femoral bypass. Variability in flow velocities over time
did not influence the likelihood of graft failure. Although
we did not identify an independent factor that absolutely
predicts graft failure, it does appear low flow velocities are a
risk factor for thrombosis and higher velocities portend
continued patency.
We thank Gary J. Sexton, PhD, for his assistance with
the statistical analyses.
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DISCUSSION
Dr Robert B. Rutherford (Silverthorne, Colo). This may be
just a matter of semantics. You’ve called these axillofemoral bypass
grafts, but what you’ve described is axillobifemoral bypass grafts.
And as Frank LoGerfo showed many years ago, the flows are almost
double between the two grafts depending on their outflow. So I
assume that your data all apply to axillobifemoral bypass grafts. Is
that correct?
And if so, do you have any observations with the axil-
lounifemoral bypass grafts that could shed some light on the quite
different flow rates one might expect in a unilateral graft?
Dr Scott E. Musicant. We looked at both axillobifemoral
and axillounifemoral grafts, but we took into account whether or
not they had a femorofemoral bypass in the multivariate analysis. In
this study the presence of a femorofemoral bypass did not influence
patency.
Dr Rutherford. So what you’re actually saying is, it’s not
true, that if you have quite a different outflow in terms of
resistance that you’re not going to have different flow velocities
in the main stem of the graft going axillounifemoral versus
axillobifemoral?
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Dr Musicant. Flow depends on resistance and pressure. You
would think that having increased outflow would improve flow,
but our data didn’t show that. Our results showed that whether a
patient had a patent superficial femoral artery or a femorofemoral
bypass didn’t seem to affect patency.
Dr Rutherford. That’s quite surprising really.
Dr Frank W. LoGerfo (Boston, Mass). I just wanted to
comment on why the peak systolic velocity seems to decrease as
you go down the graft. Consider that for any mean flow rate, when
you have disturbed flow, as at an inflow anastomosis, there is going
to be a peak systolic velocity that’s higher than where you have
more laminar flow.
The entry effects are such that even with a straight tube, you
need about 10 graft diameters before the flow disturbance settles
down, so that would be 8 cm for an 8-mm graft. But you have that
curve that you put in just downstream from the axillary anastomo-
sis, so it takes a little more distance for things to settle out. I just
wanted to make that point. That’s why the peak systolic velocity
goes down, but obviously the volume flow rate is exactly the same
at the two points.
Dr Musicant. That is correct, we looked at some of the
Doppler spectral flows and it does take a short distance from the
anastomotic area for the flow to become laminar again. At the
anastomosis the flow is turbulent.
Dr George Andros (Encino, Calif). I wanted to ask you
about data that you seem to have but you haven’t mentioned.
Could you give us some idea about angiographic and clinical
correlates to patency? For example, did you find that the patients,
very simply, with a popliteal pulse, did better than the patients who
had no popliteal pulse?
Dr Musicant. We did not look at the question of popliteal
pulses. A significant percentage of the patients whose grafts oc-
cluded did not have an angiogram because often these patients are
taken emergently to surgery and a new axillofemoral graft is placed
without performing a preoperative angiogram. Therefore, the
angiographic findings were not included in the multivariate analy-
sis because there wasnt always sufficient data available.
Dr Alun H. Davies (London, United Kingdom). Can I just
ask you two questions?
One, was the size of your grafts the same in all cases? Because
that might well influence your velocity measurements.
And secondly, you’ve identified an at-risk group. But without
a focal lesion to repair, what are you going to do about this
high-risk group even if you found it?
Dr Musicant. 8-mm grafts were used in all patients. How-
ever, the length of the graft depends on the patient, so that varies.
Based on this data, patients with a mid-graft velocity of less
than 80 cm/sec appear to a high-risk population for occlusion. A
prospective study should be done in which the patients who have
velocities less than 80 cm/sec undergo an angiogram to see if see a
lesion can be identified and repaired. If a lesion is not identified
then those patients should be considered for warfarin anticoagula-
tion.
Dr Robert M. Zwolak (Lebanon, NH). I’m curious why
low velocities are bad when they don’t seem to be that low, 80
cm/sec, ordinarily we wouldn’t consider that low. You studied the
proximal anastomosis, but have you studied the inflow more
proximal, more central to that, looking for a lesion? In our group,
we’ve taken to looking at the innominate and the subclavian and
found a significant number of inflow stenoses and ax-bifem bypass
grafts and recently have started intervening with some regularity
on innominate and subclavian stenoses where the peak velocities
may be 350 or 400. Have you looked at the inflow as a potential
source or explanation?
Dr Musicant. We haven’t looked at the proximal inflow in
patients with low velocities. Our practice has been to obtain an
angiogram when we see an abnormally high velocity at the proxi-
mal anastomosis. Often we don’t identify a stenosis, even though
there is high velocity. Like you, we tend to treat inflow arteries with
very high velocities and an identifiable stenosis.
Dr Joseph L. Mills (Tucson, Ariz). Two quick questions.
First, did you find any lesions on your surveillance? In addition to
defining graft flow velocities in the mid-graft, did you identify any
stenoses in the inflow or outflow arteries or at the anastomoses? If
you didn’t, what did you find when you thrombectomized or
revised those grafts?
The second question is how do you explain your data? Accord-
ing to the old concept of a thrombotic threshold velocity, as the
flow velocity gets lower, the graft is more likely to occlude,
especially with a prosthetic graft. But if you examine, for example,
femoropopliteal bypass patency for prosthetic grafts, it is better
with 8-mm grafts than with 6-mm grafts. All things being equal, an
8-mm graft is going to have a lower flow velocity. So how do you
explain that?
Dr Musicant. As far as identified lesions, we rarely do throm-
bectomies, so we dont know whether or not there were lesions
present. Typically, we replace the entire graft because graft replace-
ment is associated with a higher limb salvage and patency rate than
thrombectomy.
I dont know why 8 mm prosthetic grafts do better than 6 mm
grafts in the fem-pop position. I wonder if the 8 mm grafts are used
in overall larger arteries than the 6 mm grafts and therefore the flow
through the graft is higher. Perhaps it is volume rather then
velocity that matters.
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